Degarelix

證據等級: L5

預測適應症: 10 個

Degarelix: From Prostate Cancer to Hypertrichosis

One-Sentence Summary

Degarelix (Firmagon) is a GnRH receptor antagonist approved internationally for advanced prostate cancer, suppressing testosterone to castrate levels; it has no current registration in India. The TxGNN model predicts it may be effective for Hypertrichosis, with no clinical trials and no supporting publications currently available for this specific indication. The evidence base is limited to model prediction alone, warranting a Hold decision at this stage.

Quick Overview

Item	Content
Original Indication	Advanced prostate cancer (international approval; not marketed in India)
Predicted New Indication	Hypertrichosis
TxGNN Prediction Score	99.99%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current evidence pack. Based on established pharmacology, Degarelix is a competitive GnRH (gonadotropin-releasing hormone) receptor antagonist. By directly blocking pituitary GnRH receptors — without the initial hormonal surge (“flare”) seen with GnRH agonists — it rapidly suppresses LH and FSH secretion, driving testosterone to castrate levels within days. This makes it effective in advanced prostate cancer, where tumour growth is androgen-dependent.

The predicted new indication, hypertrichosis, refers to excessive hair growth occurring independently of androgen stimulation. This is a critical distinction from hirsutism, which is androgen-driven and would theoretically be more responsive to androgen deprivation. Hypertrichosis is most commonly congenital (e.g., Ambras syndrome), drug-induced, or paraneoplastic in origin — conditions where the HPG axis plays no primary pathogenic role.

While androgens do modulate hair follicle cycling in certain regions, the mechanistic bridge between GnRH receptor antagonism and non-androgenic hypertrichosis is weak and indirect. The high TxGNN score (99.99%) likely reflects network-level associations between this drug class and hair-related phenotypes in the knowledge graph, rather than a direct therapeutic mechanism. At present, this prediction lacks the biological rationale to justify clinical investigation.

Clinical Trial Evidence

Currently no related clinical trials registered for Degarelix in hypertrichosis.

Literature Evidence

Currently no related literature available for Degarelix in hypertrichosis.

Cytotoxicity

Degarelix is used in the treatment of advanced prostate cancer and falls within the oncology drug category.

Item	Content
Cytotoxicity Classification	Hormonal/Targeted therapy (GnRH receptor antagonist) — not conventional cytotoxic
Myelosuppression Risk	Low (mechanism does not involve bone marrow suppression)
Emetogenicity Classification	Low
Monitoring Items	Serum testosterone, PSA, liver function tests, QTc interval (ECG), bone mineral density (with long-term use)
Handling Protection	Standard precautions; does not require cytotoxic drug handling protocols

Safety Considerations

Drug Interactions: Degarelix has 217 documented interactions in the DDI database. A key pattern is QT interval prolongation risk, as Degarelix itself can prolong QTc. Co-administration with the following drugs carries the most clinically significant concern:

Interacting Drug	Severity	Clinical Relevance
Cisapride	Major	Additive QT prolongation; risk of torsades de pointes
Dolasetron	Major	Additive QT prolongation; cardiac arrhythmia risk
Clarithromycin	Moderate	QT prolongation and CYP3A4 inhibition
Levofloxacin	Moderate	Additive QT prolongation
Ondansetron	Moderate	Additive QT prolongation
Granisetron	Moderate	Additive QT prolongation
Palonosetron	Moderate	Additive QT prolongation
Famotidine	Moderate	Electrolyte effects may compound QT risk

Please refer to the package insert for complete safety information including key warnings and contraindications. Full TFDA/CDSCO prescribing information was not available in the current evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN model assigns a 99.99% prediction score, this reflects mathematical confidence within the knowledge graph model — not clinical evidence. Hypertrichosis is predominantly a non-androgenic disorder, and no clinical trials, observational studies, or mechanistic publications support the use of GnRH antagonism for this condition. The drug is also not registered in India, adding a further regulatory barrier.

To proceed, the following is needed:

Obtain full package insert (TFDA/EMA Firmagon SmPC) to complete safety profiling (warnings, contraindications)
Retrieve DrugBank MOA entry to formally characterise mechanism and explore class-level evidence
Conduct a focused literature review on androgenic vs. non-androgenic hypertrichosis subtypes to determine whether any subgroup could benefit from androgen suppression
If sub-indication of interest shifts to hirsutism (androgenic type) or central precocious puberty (Rank 9, L4 evidence), the mechanistic rationale becomes substantially stronger and may warrant a Research Question designation
Assess feasibility of India regulatory registration as a prerequisite for any clinical programme
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.